Blue Shield of Calif. is bypassing traditional pharmacy benefit managers to bring a Humira-referenced biosimilar, Idacio, to ...

Though we’ve recently observed some improvement in U.S. biosimilar penetration, market entry and uptake still consistently ...

Their discoveries have already led to the departure of a Stanford president, sparked charges from the Department of Justice, ...

The story with AbbVie (NYSE: ABBV) in 2024 is that it fell off a patent cliff but survived. It survived and continues to ...

When patents for name brand medicines expire, the price of that medicine drops significantly as generic versions enter the market, but that process can take a while.

(Reuters) -Cigna projected 2025 profit growth of at least 10% on Thursday, after posting quarterly results that beat Wall ...